404882-00-4
Chemical Structure
Obtustatin
- CAS No.: 404882-00-4
- Formula:C184H284N52O57S8
- Molecular Weight:4393.06
SMILES: O=C([C@@H](N)CSSC[C@H](NC1=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N2[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]3CC4=CC=C(O)C=C4)=O)CC5=CNC=N5)=O)CO)=O)[C@@H](C)O)=O)CC(C)C)=O)CO)=O)[C@@H](C)O)=O)CCCCN)=O)CC6=CNC7=CC=CC=C67)=O)CSSC[C@H](NC8=O)C(N9[C@H](C(N[C@H](C(N[C@H](C(N%10[C@H](C(NCC(O)=O)=O)CCC%10)=O)CC%11=CC=C(O)C=C%11)=O)CC(C)C)=O)CCC9)=O)=O)[C@@H](C)O)=O)[C@@H](C)O)=O)=O)C)=O)CCC2)=O)CCCCN)=O)CC(C)C)=O)CCCCN)=O)N[C@H](C(N[C@H](C(NCC(N%12[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]1CCC(N)=O)=O)CCCNC(N)=N)=O)CSSC[C@H](NC%13=O)C(N[C@H]8CC(O)=O)=O)=O)CSSC[C@H](NC3=O)C(N[C@H](C(NCC(NC(C(NC%13CO)=O)CCCCN)=O)=O)[C@@H](C)O)=O)=O)CCC%12)=O)=O)[C@@H](C)O)=O)[C@@H](C)O
Biological Activity: Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Obtustatin | 99.94% | Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Marcinkiewicz C, et al. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res. 2003 May 1;63(9):2020-3. [Content Brief]
- [2]. Ghazaryan N, et al. The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model. Invest New Drugs. 2019;37(5):1044-1051. [Content Brief]
- [3]. Paz Moreno-Murciano M, et al. NMR solution structure of the non-RGD disintegrin obtustatin. J Mol Biol. 2003;329(1):135-145. [Content Brief]
